Tekla Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Tekla Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-35,743	Closed	-$1.72M	–	228
2020 Q1	$1.72M	Sell	35,743 -20,086	-36%	-$934K	0.08%	144
2019 Q4	$2.62M	Hold	55,829	–	–	0.1%	140
2019 Q3	$1.32M	Buy	55,829 +36,639	+191%	+$1.09M	0.06%	147
2019 Q2	$577K	Buy	+19,190	New	+$440K	0.02%	179
2018 Q3	–	Sell	-219,952	Closed	-$2.19M	–	216
2018 Q2	$2.19M	Sell	219,952 -118,613	-35%	-$819K	0.08%	134
2018 Q1	$1.8M	Sell	338,565 -17,672	-5%	-$126K	0.07%	142
2017 Q4	$3.03M	Sell	356,237 -39,581	-10%	-$487K	0.12%	109
2017 Q3	$5.78M	Hold	395,818	–	–	0.21%	82
2017 Q2	$7.42M	Buy	+395,818	New	+$8.93M	0.27%	70

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Tekla Capital Management's RARX Position: Q2 2020 in Review

Tekla Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 35,743 shares — an estimated $1.72M sold.

Tekla Capital Management first reported a position in RARX in Q2 2017 and held it in 9 quarters. The position peaked at $7.42M in Q2 2017. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Tekla Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Tekla Capital Management sold 35,743 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.72M.
Tekla Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Tekla Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $7.42M in Q2 2017.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.